Company / Cost of Revenue
Edesa Biotech, Inc. Cost of Revenue History
FY2014-FY2021 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Cost of Revenue
$17.6K
FY2021
5-year range
$17.6K / $580.8K
FY2017-FY2021
Trend
-82.6%
vs FY2020
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Cost of Revenue has declined for 3 consecutive years, from $580,824 in FY2017 to $17,601 in FY2021.
Based on SEC 10-K filings.
$17,601 in FY2021 with a 5-year CAGR of -48.1%.
Improved from $250,042 to $17,601 over the past 3 years.
Cost of Revenue over time
Growth rates
- 3-Year CAGR
- -58.7%
- 5-Year CAGR
- -48.1%
- 10-Year CAGR
- -
Key checks
Key Insights
- Edesa Biotech, Inc.'s cost of revenue has declined for 3 consecutive years.
- 5-year CAGR of -48.1%, indicating a declining trend.
- In FY2021, cost of revenue decreased 82.6% year-over-year.
- Peak cost of revenue was recorded in FY2017.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -0.47 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Cost of RevenueValue | YoY GrowthYoY |
|---|---|---|
| FY2021 | $17.6K | -82.6% |
| FY2020 | $101.3K | -59.5% |
| FY2018 | $250.0K | -57.0% |
| FY2017 | $580.8K | +23.8% |
| FY2016 | $469.1K | +718.0% |
| FY2015 | $57.4K | -86.5% |
| FY2014 | $426.3K | - |
As of FY2021 · SEC 10-K · Updated Jun 24, 2026